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Pertussis toxin (PT) is considered an essential protective component for incorporation into new generation
vaccines against BordeteUla pertussis, the causative agent of whooping cough. Traditionally, antipertussis
vaccination has employed an intramuscular route. An alternative to this approach is to stimulate mucosal and
systemic immune responses by oral immunization with live vaccine carrier strains of SalmoneUla spp. or
Escherichia coli. Recombinant Si subunit of pertussis toxin was expressed in the attenuated aroA mutant of
SalmoneUla typhimurium, SL3261, in the human typhoid vaccine strain SalmoneUa typhi Ty2la, and in E. coli
CAG629 containing the Shigela flexneri plasmid pWR110, which encodes bacterial invasiveness of epithelial
cells. Expression of recombinant PT S1 subunit (rPT-S1) did not affect in vitro invasiveness of the tested
strains, which retained the ability to adhere to and invade the embryonic human intestinal cell line HI-407.
Following oral immunization of mice with the live vaccine strains expressing rPT-S1, immunoglobulin G (IgG),
IgA, and IgM responses were monitored. IgG specific to PT was detected in serum samples of mice, while IgG
and IgA specific to PT were detected in lung washes after oral immunization with living Sabnonella spp. or E.
coli (pWR110) expressing rPT-S1. Utilization of live oral vaccines expressing B. pertussis antigens, which
stimulate both a systemic and lung mucosal response, may provide an attractive alternative to purified
component vaccines against whooping cough.
Bordetella pertussis is the causative agent of whooping
cough, a particularly severe disease of infants characterized
by repeated bouts of paroxysmal coughing. Until recently,
this disease has been controlled through vaccination. How-
ever, mounting concerp about side effects associated with
immunization with heat-killed, whole-cell vaccine prepara-
tions has lead to decreased vaccine acceptability and a
disturbing rise in the incidence of the disease in recent years.
There is, therefore, an urgent need to develop new, nonre-
actogenic, and effective vaccines against pertussis.
Virulence factors produced by B. pertussis that are can-
didates for inclusion in new generation vaccines include
pertussis toxin (PT) and filamentous hemagglutinin (FHA)
(22). The importance of these antigens as vaccine compo-
nents has been emphasized in several animal models (11, 19).
Unfortunately, human trials with acellular vaccine prepara-
tions composed of both of these components failed to elicit a
fully efficacious response despite their ability to induce
humoral immunity (1, 16, 34).
Antipertussis vaccination has traditionally employed an
intramuscular route, mainly stimulating a systemic response.
An alternative approach would be to stimulate an immune
response directly at the lung epithelial surface. This would
have the additional benefit of helping to reduce B. pertussis.
colonization. We have recently demonstrated that the stim-
ulation of gut immunity by using recombinant vaccine carrier
strains of Salmonella typhimurium and invasive Escherichia
coli expressing plasmid-encoded FHA results in the produc-
tion of specific mucosal immunity at the lung epithelial
* Corresponding author.
surface (6, 7). As an extension of these observations to other
potential B. pertussis vaccine components, we report here
expression of a recombinant Si subunit of PT (rPT-Sl) in the
attenuated aroA mutant of S. typhimurium, SL3261, in the
human typhoid vaccine strain Salmonella typhi Ty2la, and
in an E. coli strain containing the Shigella flexneri plasmid
pWR110, which codes for bacterial invasiveness of epithelial
cells. Both PT-specific systemic and lung mucosal antibody
responses were obtained following oral immunization with
these live vaccine carrier strains.
MATERIALS AND METHODS
Bacterial strains, plasmids, and media. The bacterial
strains used in this work were B. pertussis Tohama 1 (29), E.
coli JM109 (37), E. coli CAG629 lon htpR165-Tn1O (C.
Gross), E. coli K-12 395-1 (27), S. typhimurium aroA mutant
SL3261 (10), S. typhimurium SL5283 (B. Stocker), agalE503
derivative of LB5000 hsdSB121 leu-3121 (26), and S. typhi
Ty2la (5). The plasmids used in this work were pTX42 (14),
which was a kind gift from J. Keith and was used as a source
of the PT operon; pUC18 (37), pWR110, and R64drdll (8,
27, 28); and pJLA506 (M. Walker), a derivative of the
expression plasmid pJLA503 (31) with a modified multiple-
cloning site.
E. coli was grown on Luria agar or 5-bromo-4-chloro-3-
indolyl-p-D-galactopyranoside (X-Gal) agar or in Luria broth(25), and S. typhimurium strains were grown on Luria agar
or in Luria broth (25). S. typhimurium Ty2la was grown on
Luria agar or in brain heart infusion broth containing 0.001%
galactose. Broth cultures were grown with shaking at 200
rpm. B. pertussis Tohama I was grown on Bordet Gengou
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agar base (Difco) supplemented with 1% glycerol and 15%
(vol/vol) defibrinated horse blood or in SS-X broth (33).
Antibiotics were used at the following concentrations: ampi-
cillin, 100 p,g/ml; tetracycline, 50 p,g/ml; and kanamycin, 50
,ug/ml. Broth cultures were aerated by shaking at 300 rpm in
a New Brunswick Environmental Incubator Shaker.
DNA manipulations, plasmid transfer, and induction exper-
iments. Restriction endonucleases and T4 DNA ligase were
used as previously described (25). Plasmid isolation and
transformation were performed as described by Sambrook et
al. (25). Taq polymerase was used as described by Scharf
(30). The polymerase chain reaction primers S1-5'NdeI
(5'-GGCATA3XCGTTGCACTCGGGCAATT-3') and S1-
3'XbaI (5'-CCAGGTCTAGAACGAATA-3') used for clon-
ing the Si subunit cistron as a NdeI-XbaI fragment (NdeI
and XbaI sites, respectively, are underlined) were synthe-
sized with an Applied Biosystems Model 380B DNA synthe-
sizer in accordance with the manufacturer's instructions.
Conjugal transfer of pWR110 (Kmr) to E. coli CAG629 was
accomplished by using the mobilizing helper plasmid R64-
drdll (Tcr) as previously described by Sansonetti et al. (27,
28). Induction experiments were performed as previously
described by Guzmain et al. (7). Sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) of whole-
cell extracts was performed as described by Laemmli (12).
Electron microscopy. For postembedding labelling, cells of
the respective strains were fixed directly in Luria broth with
a fixation solution containing 0.5% (vol/vol) formaldehyde
and 0.3% (vol/vol) glutaraldehyde in phosphate-buffered
saline (PBS; 0.1 M phosphate buffer, 0.9% NaCl [pH 7.0])
for 1 h on ice. After being washed with PBS containing 10
mM glycine, the samples were embedded into 1.5% (wt/vol)
agar. After solidification of the agar, small cubes were cut
and embedded with progressive lowering of the temperature
by using Lowicryl K4M resin (23). Immunolabelling was
done with a 1:25 dilution of the purified rabbit PT-specific
immunoglobulin G (IgG) antibody (200 ,ug of IgG protein per
ml) (36) by incubating ultrathin sections on drops of the
diluted antibody for 5 h at room temperature. After being
washed with PBS, the bound antibodies were made visible
with protein A-gold complexes (10-nm-diameter gold particle
size, 30-min incubation time), prepared by established pro-
cedures (32). Subsequently, the sections were washed with
PBS containing 0.01% Tween 20, and the sections were air
dried prior to being stained with 4% (wt/vol) uranyl acetate
for 3 min. Electron micrographs were examined, and micro-
graphs were taken with a Zeiss EM1OB electron microscope
at an acceleration voltage of 80 kV and at calibrated magni-
fications.
Tissue culture methods and in vitro adhesion and invasion
assays. The human embryonic intestinal cell line Intestine
407 (ATCC CCL 6, designated HI-407 in this work; GIBCO
Laboratories, Eggenstein, Germany) was maintained in Dul-
becco's modified Eagle medium (DME; GIBCO) with 10%
fetal calf serum (GIBCO), 5 mM glutamine (Flow), and 1 mM
pyruvate (Flow), in an atmosphere containing 5% CO2 at
37°C. Trypsinized cells were seeded at a concentration of
approximately 2 x 105 cells per coverslip (15 by 15 mm) in
tissue culture plates (12 by 4.5 cm2; Flow). These were
incubated for 18 to 24 h and then washed three times in PBS
(per liter, 8.0 g of NaCl, 2.0 g each of KCl, Na2HPO4 .2H20,
and KH2PO4 [pH 7.4]). For infection of monolayers, bacte-
ria were harvested by centrifugation in the exponential
growth phase, resuspended to a density of 108 CFU/ml in
DME, overlaid onto the monolayer of cells on coverslips,
and incubated for 45 min at 37°C with 5% CO2. Unattached
and loosely attached bacteria were removed by washing the
monolayers three times with PBS. For adhesion assays, the
monolayers were then stained with Giemsa solution and
examined by light microscopy, and the mean number of
bacteria per HI-407 cell was calculated by averaging the
number of bacteria adhering to 40 cells by using light
microscopy. For invasion assays, DME containing gentami-
cin (100 ,ug/ml) was then added; this concentration of genta-
micin killed extracellular bacteria and thereby prevented any
reinfection of cells. Monolayers were incubated for an
additional 3-h period and then washed three times with PBS.
The number of invading bacteria was determined by lysing
the eukaryotic cells with the addition of 1 ml of 1% Triton
X-100 (vol/vol) to each well and calculating viable counts on
Luria agar plates.
Mouse immunization. Six- to seven-week-old female
BALB/c mice were immunized and caged separately in
groups of five. Mice were immunized according to the
protocols given in Table 2. The groups were immunized with
one dose on day 0 and boosted with identical doses 30 and 40
days later. The animals were sacrificed 10 days after the last
booster, and the samples were collected. For immunization
with live bacteria, E. coli CAG629 and S. typhimurium
SL3261 were grown in Luria broth, while S. typhi Ty2la was
grown in brain heart infusion broth containing 0.001% galac-
tose and B. pertussis Tohama I was grown in SS-X medium.
An overnight liquid culture of bacteria was diluted 100-fold
with broth containing an appropriate antibiotic for selection,
and the fresh culture was incubated at 37°C until it reached
early logarithmic phase. The cultures were centrifuged, and
the bacteria were resuspended in PBS to an optical density
which gave the appropriate viable count (as determined
previously for each strain). For oral immunization, immedi-
ately before immunization an equal volume of 3% sodium
bicarbonate in PBS (pH 8.0) was added to the suspension.
Mice that had been deprived of water for 6 to 8 h were then
gently fed with 50 ,ul of the bacterial suspension. For
intraperitoneal (i.p.) immunizations, bacteria were sus-
pended in PBS and, if required, were heat killed by treat-
ment at 60°C for 30 min.
Sacrificed mice were exsanguinated by cutting the brachial
artery, and the serum was separated and stored at -20°C.
Lung washes were collected after pertracheal cannulation
and gentle washing with 0.7 ml of ice-cold PBS containing 2
mM phenylmethylsulfonyl fluoride as a protease inhibitor.
About 0.5 ml of lung wash was recovered from each mouse.
Lung washes were centrifuged at 3,000 x g for 5 min at 4°C
to remove debris and stored at -20°C.
Immunological techniques. Monoclonal antibody E19 (36),
which reacts with the S1 subunit of PT, was used in Western
blot (immunoblot) experiments carried out essentially as
described by Burnette (3). Proteins were transferred to a
nitrocellulose membrane by using 25 mM Tris-192 mM
glycine-20% methanol (pH 8.3) as transfer buffer and a 10%
solution of 0.3% low-fat milk in PBS (pH 7.4) as a blocking
reagent. E19 hybridoma supernatant fluid was used as the
first antibody. The detection system used was Bio-Rad
horseradish peroxidase-conjugated goat anti-mouse IgG and
4-chloro-1-naphthol as substrate.
For the determination of subclass-specific antibodies
against the S1 subunit in serum and lungs washes, enzyme-
linked immunosorbent assays (ELISAs) were performed as
follows. Nunc Maxisorp Immunomodule 96-well plates were
coated with PT (kindly supplied by S. Cryz) diluted in 0.1 M
NaHCO3 (pH 9.6) (60 ng in 50 ,ul per well) and incubated at
4°C overnight. The wells were blocked with 100 pl of 10%
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FIG. 1. Construction of plasmids specifying rPT-S1 expression. The PT operon was cloned from plasmid pTX42 (14). PT subunit genes
Si to S5 (open arrows) and the PT promoter (closed arrow) are indicated. Plasmid pUC18 contains the lactose repressor gene (LacI [open
box]), ampicillin resistance gene (Amp [open box]), lac promoter (PLAC [closed arrow]) and 3-galactosidase alpha fragment sequence (B-gal
[open box]). The expression vector pJLA506 contains the lambda PL and PR promoters in tandem (PL and PR [closed arrows]),
temperature-sensitive lambda repressor gene (cIts857 [open box]), fd transcriptional terminator (fd [cross-hatched box]), and ampicillin
resistance gene as described for pUC18. The direction of transcription is indicated by either thin arrows or the orientation of open arrows.
Plasmids are not drawn to scale, and only relevant restriction sites are shown.
fetal calf serum in PBS for 2 h at 37°C. Plates were
subsequently washed three times with PBS, and 100 p.l of
serum samples (diluted 1:25) or lung washes (diluted 1:10) in
10% fetal calf serum in PBS was added to each well. After 2
h at 37°C, the plates were again washed, and 100 pul of
alkaline phosphatase-conjugated goat anti-mouse antibodies
for IgG, IgM, or IgA heavy chains (Southern Biotechnology
Associates, Inc.) diluted 1:300 in 10% fetal calf serum in PBS
was added to each well and incubated for 2 h at 37°C. The
plates were again washed and then developed by the addition
cl
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FIG. 2. Analysis of rPT-Si expression by recoml
strains. Whole-cell extracts of S. typhimurium SL
(lanes 2 and 3), S. typhi Ty2la(pMW151) (lanes 4 and
CAG629(pMW151) (lanes 6 and 7) are shown, as are a
penrussis Tohama I (lane 8) and purified PT (lane
samples loaded onto lanes 2, 4, and 6 were induced a
while for samples in lanes 3, 5, and 7, bacteria were I
(A) Coomassie blue-stained gel of whole-cell extract
blot analysis of whole-cell extracts using the anti-I
antibody E19. The positions are of the PT Si subuni
by arrows. All lanes in panels A and B were loaded
amount of material except lane 1, in which 50-fol
loaded for panel B than for panel A.
of 100 p,l of substrate solution (1.0 mg ofp-nitr(
phate, disodium salt, in diethanolamine buffer
well. After 30 min at room temperature, the
stopped by the addition of 50 ,ul of 3.0 M NaOH,
was determined with a Titertek Multiskan MC
reader (Flow). All the samples were proces
neously on the same day, each serum or lung
was individually assayed, and normal nonimmu
sera or lung washes were used as the blank fo
readings. Results are expressed as the mean va
group.
RESULTS
Construction of rPT-S1 expression plasmids.
eron, originating from plasmid pTX42 (14), w
polymerase chain reaction template to amplif
subunit. The polymerase chain reaction prime
and Si-3'XbaI were used to amplify a DNA fi
taining the ATG start codon of the S1 gene inco
the NdeI restriction endonuclease cleavage s
primer. The 3' primer contains the XbaI site fo
end of the wild-type Si subunit DNA sequ
incorporates the TAG stop codon of the gene.
screening clones containing the PCR product, ti
fragment containing the Si structural gene was (
NdeI and XbaI restriction enzymes and cloned firstly into
7 8 analogous sites found in pUC18 to produce pMW150. Sub-
sequently, the Si structural gene was purified and cloned as
an NdeI-EcoRI fragment into the corresponding sites of
expression vector pJLA506 to construct pMW151 (Fig. 1).
This plasmid contains the Si structural gene downstream of
the efficient atpE ribosome binding site and tandem lambda
PL and PR promoters under the control of the temperature-
sensitive cI repressor protein, i.e., under a heat-inducible
expression system.
Production of rPI-S1 in Sabnonella spp. and E. coli. The
expression plasmid pMW151 was transformed into the Ion
and htpR protease-deficient E. coli CAG629 and S. typhimu-
rium SL5283. Plasmid DNA isolated from the latter was used
7 8 to transform S. typhimunium SL3261 and S. typhi Ty2ia.After induction at 42°C for 1 h, whole-cell extracts were
subjected to SDS-PAGE and Western blotting with the
Sl-specific monoclonal antibody E19 (36). rPT-Si and a
degradation product of rPT-Si migrating as a slightly lower
band were detected at levels significantly higher than those
found for B. pertussis Tohama I (Fig. 2). Lower levels of
rPT-Sl were detected in recombinant strains after induction
at 37°C for 24 h (results not shown).
Immunoelectron microscopy of E. coli CAG629 and S.
typhi Ty2ia containing either pJLA506 or pMW151 demon-
strated that, after induction, inclusion bodies are not formed
3b261antMWccn) and that rPT-Sl is accumulated at the periphery of pMW151-
5), and E. coli bearing strains of E. coli CAG629 and S. typhi Ty2ia (Fig.
n extract of B. 3A, B, D, and E), indicating that the leader peptide of the Si
1). Bacteria in subunit is correctly processed, as previously described (4).
at 42°C for 1 h, Outer membrane ghosts of E. coli CAG629(pMW151) are
grown at 30°C. labelled with gold particles, indicating that the rPT-Si sub-
:s; (B) Western unit is translocated through the cytoplasmic membrane into
?T monoclonal the periplasmic space and may be associated with the outeritare indicated membrane (Fig. 3C). For S. typhimurium SL3261(pMW151),
d-less PT was the label is detectable only in the cytoplasm (Fig. 3F). Other
recombinant proteins including the Shiga toxin B subunit
and a mycobacterial outer membrane protein were also
expressed exclusively in the cytoplasm of this strain,
c)phenylphos- whereas in wild-type S. typhimurium, these proteins were
[pH 9.8]) per localized at the cell periphery (22a). It is not yet clear
reaction was whether the aroA mutation or other strain-specific differ-
, and theA405 ences influence secretion of rPT-Si in SL3261.
'C microplate Ability of recombinant strains to adhere to and to invade the
ised simulta- embryonic human intestinal cell line HI407. The presence of
wash sample plasmid pMW151 affected neither the ability of S. typhimu-
mized mouse rium SL3261 and S. typhi Ty2ia to adhere to the embryonic
ir the ELISA human intestinal cell line HI-407 nor the ability to invade
blues for each such cells (Table 1). The S. flecneri plasmid pWR110, which
carries genes required for bacterial invasion of epithelial cells,
was conjugally transferred to E. coli CAG629 (pMW151) to
produce E. coli CAG629(pMW151 and pWR110). The pres-
ence of pWR110 resulted in the conversion of this strain to
The PT op- an invasive phenotype. Adhesion and invasion assays gave
ras used as a comparable results, although E. coli CAG629(pMW151 and
.y the PT S1 pWR110) gave a higher adhesion assay response than either
:rs Sl-5'NdeI Salmonella spp. but a comparatively lower invasion assay
ragment con- response (Table 1). This anomaly was not observed in
orporated into similar experiments conducted with another E. coli strain (6)
;ite of the 5' and may represent strain-dependent differences which result
und at the 3' in a decreased ability to survive intracellularly.
ience, which Assessment of specific anti-PT antibody responses in vacci-
To facilitate nated mice. After the introduction of the rPT-Si expression
ieNdeI-XbaI plasmid pMW151, both types of vaccine delivery system
digested with tested in this study, attenuated Salmonella spp. and E. coli
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TABLE 1. In vitro adhesiveness and invasiveness of strains
used in vaccination protocols
Strain Adhesivenessa Invasiveness"
SL3261 18.2 + 4.3 4.8 x 1± 1,166
SL3261(pMW151) 17.8 ± 3.8 6.8 x 103 ± 909
Ty2la 11.0 + 3.4 1.6 x 104 ± 2,582
Ty2la(pMW151) 10.6 ± 3.1 1.3 x 104 ± 2,160
CAG629 3.7 ± 2.5 <.25c
CAG629(pMW151) 3.2 ± 2.7 <25c
CAG629(pMW151 and pWR110) 31.7 ± 7.0 4.0 x 102 + 18
a Mean number of attached bacteria per HI-407 cell ± standard deviation.
bCFUJ of viable intracellular bacteria per coverslip ± standard deviation.
c Limit of detection.
bearing the S. flexneii invasion plasmid pWR110, elicited
anti-PT antibody responses (Table 2; Fig. 4). The i.p. immu-
nization of mice with either 106 heat-killed B. pertussis cells
or 106 live S. typhimunium SL3261(pMW151) cells induced
similar, high serum and lung mucosal IgG antibody levels but
insignificant amounts of IgA. However, higher IgM re-
sponses were engendered by live S. typhimunrium SL3261
(pMW151) compared with heat-killed B. pertussis after i.p.
immunization (compare groups a and c in Fig. 4).
Oral immunization with 109 live S. typhimuinum SL3261
(pMW151), S. typhi Ty2la(pMW151), or E. coli CAG629
(pWRllO and pMW151) elicited high systemic IgG and low
systemic IgA levels, similar to those levels found after i.p.
immunizations (compare groups a and c with groups e, f, and
h in Fig. 4A), and elevated anti-pertussis toxin IgA levels in
lung washes. The amounts of IgG and IgA in lung washes
were found to be highest after oral immunization with S.
typhimurium SL3261(pMW151), followed by S. typhi Ty2la
(pMW151), and were lowest after immunization with E. coli
CAG629(pWR110 and pMW151) (compare groups e, f, and h
in Fig. 4B). This variation may reflect strain differences in
the ability to persist in mice. The absence of plasmid
pWRllO from E. coli CAG629(pMW151) was associated
with a marked decrease in the anti-PT response (compare
groups g and h in Fig. 4). Presumably a lack of the invasion
plasmid prevents an adequate antigen presentation to the
gut immune system by E. coli CAG629(pMW151). Signifi-
cant IgM responses were not apparent for any strain after
oral immunization (groups d to h in Fig. 4).
DISCUSSION
Whooping cough is a severe respiratory tract disease.
Traditional antipertussis vaccination has employed the intra-
muscular route. However, it may be desirable to develop
vaccines which stimulate not only specific serum responses
but also specific IgA in the respiratoxy tract. The production
of lung mucosal secretory antibodies may interfere with the
attachment of B. penussis and subsequent colonization and
thereby help prevent infection as well as disease. Such a
vaccine would additionally favor eradication of a disease for
which there is only a human reservoir. Serological studies of
TABLE 2. Mouse immunization protocols
Groupa Organism or strain Dose6 Routec Viability ofbacteria
a B. pertussis Tohama I 106 i.p. Heat killed
b SL3261 106 i.p. Live
c SL3261(pMW151) 106 i.p. Live
d SL3261 109 Oral Live
e SL3261(pMW151) 109 Oral Live
f Ty2la(pMW151) 109 Oral Live
g CAG629(pMW151) 109 Oral Live
h CAG629(pMW151 and pWR110) 109 Oral Live
a Group designation as in Fig. 4.
b Total number of bacteria per mouse.
c i.p., intraperitoneal injection; Oral, orally administered dose.
patients with whooping cough have revealed increases in
both IgG and IgA levels against specific B. pertussis viru-
lence determinants. On the other hand, whole-cell vaccines
engender weak, if any, specific IgA (34). The mucosal
immunological network contains subpopulations of lym-
phoid cells with the ability to migrate from the intestine to
other distant mucosa (i.e., the respiratory tract) (2, 15, 24).
Therefore, the development of enteric delivery systems for
pertussis antigens which stimulate both a systemic and lung
mucosal response may not only result in the prevention of
infection and disease, and thus provide an attractive alter-
native to purified component vaccines against whooping
cough, but also eliminate the need for purification of indi-
vidual vaccine components for this purpose. The purification
of individual vaccine components may be cost prohibitive
for use in Third World countries.
We have recently demonstrated that stimulation of gut
immunity by using recombinant S. typhimurium aroA
SL3261 expressing the 220-kDa FHA protein resulted in a
specific secretory IgA response at the lung mucosal surface
(6, 7). Another group of investigators was unsuccessful in
engendering a lung mucosal immune response after oral
immunization of mice with Salmonella spp. expressing trun-
cated FHA (17, 20). The inability to detect lung mucosal
responses in these previous studies may reflect problems of
plasmid instability or the expression level of recombinant
FHA obtained. Our ability to detect a mucosal immune
response may also have been due to an increased immuno-
genicity of the native protein compared with the truncated
forms of FHA expressed in the earlier studies (17, 20).
PT is considered an essential protective component for
new generation vaccines against whooping cough. In our
present study, rPT-Sl was expressed in the attenuated aroA
mutant of S. typhimurium, SL3261, in the human typhoid
vaccine strain S. typhi Ty2la, and in E. coli CAG629
containing the S. flexneri plasmid pWR110, which encodes
for bacterial invasiveness of epithelial cells. Expression of
rPT-Sl did not affect in vitro invasiveness of HI407 cells by
the tested strains. Following oral immunization of mice with
the live vaccine strains expressing rPT-S1, IgG specific to PT
was detected in serum samples of mice while IgG and IgA
FIG. 3. Immunoelectron microscopic localization of the rPT-S1 subunit. Ultrathin sections were treated with polyclonal rabbit anti-PT IgG
antibodies; bound antibodies were visualized with protein A-gold complexes. Most of the gold particles (labelled G) are associated with the
cell periphery in the strains E. coli CAG629(pMW151) (A, C, and D) and S. typhi Ty2la(pMW151) (E), whereas for S. typhimurium SL3261
(pMW151), the label is located in the cytoplasm (F). Incubation of E. coli CAG629(pJLA506) with the antibodies and the protein A-gold
particles as a control experiment showed no label (B). Bars represent 0.2 ,um in panels A, B, C, E, and F and 0.1 p.m in panel D.
Abbreviations: CM, cytoplasmic membrane; OM, outer membrane.
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specific to PT were detected in lung washes. These immune
responses were detected irrespective of whether rPT-S1 was
localized in the periplasmic space (E. coli CAG629 and S.
typhi Ty2la) or in the cytoplasm (S. typhimurium SL3261).
It has been demonstrated that i.p. immunization of mice
with crude preparations of recombinant Si subunit resulted
in an anti-PT response, but mice were not significantly
protected from intracerebral challenge (4). It will be impor-
tant to determine whether oral immunization of mice with
recombinant Salmonella spp. or invasive E. coli expressing
rPT-Sl either alone or in conjunction with such strains
expressing FHA, stimulating both systemic and lung muco-
sal responses, results in a protective immune response in the
intranasal model of infection (21). An immune response
against the S2 to S5 subunits of the PT B oligomer may be
necessary to achieve protection.
Live antigen delivery systems resistant to antibiotics are
considered by the U.S. Food and Drug Administration to be
unacceptable for human use. Non-antibiotic-resistance
transposon systems which allow the stable integration and
expression of potential vaccine components, for instance
pertussis holotoxin in Bordetella bronchiseptica (35), in
antibiotic-sensitive delivery systems are, however, available
(9). Similar antibiotic-resistance "mini-transposons" have
been used to successfully integrate a gene encoding the
circumsporozoite protein of Plasmodium yoelii into the
chromosome of S. typhimurium and elicit an immune re-
sponse against the circumsporozoite protein in mice (4a).
Experiments designed to express the other PT subunits, S2
to S5, and to incorporate such expression systems into the
chromosome of the vaccine delivery strains described above
are in progress.
In this report, and in the previous studies made by
Guzmain et al. (6, 7), we have demonstrated the potential of
recombinant enteric vaccine carrier systems to stimulate
lung mucosal immune responses to B. pertussis antigens.
These results may lead to the future development of oral
vaccines against whooping cough and other infections of the
respiratory tract. Particularly encouraging is the anti-PT
response engendered by S. typhi Ty21a(pMW151), since
Ty2la has been approved for human use by the U.S. Food
and Drug Administration and is known to be a safe vaccine
(13). However, the apparent failure of Ty21a to engender an
anti-O antigen immune response in infants by using standard
doses efficacious in school children (18) indicates that alter-
native strains may be required as vaccine delivery vehicles
for infants.
ACKNOWLEDGMENTS
We thank P. J. Sansonetti for E. coli K-12 395-l(pWR110), J.
Keith for plasmid pTX42, S. Cryz for PT purified from B. pertussis,
and J. McCarthy for oligonucleotide synthesis.
This work was partially supported by a grant from the Australian
Research Council Small Grant Scheme and a German National
Research Centre international collaborative grant.
REFERENCES
1. Ad Hoc Group for the Study of Pertussis Vaccines. 1988. Placebo-
controlled trial of two acellular pertussis vaccines in Sweden-
protective efficacy and adverse effects. Lancet i:955-960.
2. Bienenstock, J., A. D. Befus, M. McDermott, S. Mirski, and K.
Rosenthal. 1983. Regulation of lymphoblast traffic and localiza-
tion in mucosal tissues with emphasis on IgA. Fed. Proc.
42:3213-3217.
3. Burnette, W. N. 1981. "Western blotting": electrophoretic
transfer of proteins from sodium dodecyl sulphate-polyacryl-
amide gels to unmodified nitrocellulose and radiographic detec-
tion with antibody and radioiodinated protein A. Anal. Bio-
chem. 112:195-203.
4. Burnette, W. N., V. L. Mar, W. Cieplak, C. F. Morris, K. T.
Kaljot, K. S. Marchitto, R. K. Sachdev, C. Locht, and J. M.
Keith. 1988. Direct expression of Bordetella pertussis toxin
subunits to high levels in Escherichia coli. Bio/Technology
6:699-706.
4a.Flynn, J. L., W. R. Weiss, K. A. Norris, H. S. Seifert, S. Kumar,
and M. So. 1990. Generation of a cytotoxic T-lymphocyte
response using a Salmonella antigen-delivery system. Mol.
Microbiol. 4:2111-2118.
5. Germanier, R., and E. Firer. 1975. Isolation and characterization
ofgalE mutant Ty2la of Salmonella typhi: a candidate strain for
a live, oral, typhoid vaccine. J. Infect. Dis. 131:553-558.
6. Guzman, C. A., R. M. BrownUlie, J. Kadurugamuwa, M. J.
Walker, and K. N. Timmis. 1991. Antibody responses in the
lungs of mice following oral immunization with Salmonella
typhimurium aroA and invasive Escherichia coli strains ex-
pressing the filamentous hemagglutinin of Bordetella pertussis.
Infect. Immun. 59:4391-4397.
7. Guzman, C. A., M. J. Walker, M. Rohde, and K. N. Timmis.
1991. Direct expression of Bordetella pertussis filamentous
hemagglutinin in Escherichia coli and Salmonella typhimunum
aroA. Infect. Immun. 59:3787-3795.
8. Hale, T. L., P. J. Sansonetti, P. A. Schad, S. Austin, and S. B.
Formal. 1983. Characterization of virulence plasmids and plas-
mid-associated outer membrane proteins in Shigella flexnei,
Shigella sonnei, and Escherichia coli. Infect. Immun. 40:340-
350.
9. Herrero, M., V. de Lorenzo, and K. N. Timmis. 1990. Transpo-
son vectors containing non-antibiotic resistance selection mark-
ers for cloning and stable chromosomal insertion of foreign
genes in gram-negative bacteria. J. Bacteriol. 172:6557-6567.
10. Hoiseth, S. K., and B. A. D. Stocker. 1981. Aromatic-dependent
Salmonella typhimurinum are non-virulent and effective as live
vaccines. Nature (London) 291:238-239.
11. Kimura, A., K. T. Mountzouros, D. A. Relman, S. Falkow, and
J. L. Coweli. 1990. Bordetella pertussis filamentous hemagglu-
tinin: evaluation as a protective antigen and colonization factor
in a mouse respiratory infection model. Infect. Immun. 58:7-16.
12. Laemmli, U. K. 1970. Cleavage of structural proteins during the
assembly of the head of bacteriophage T4. Nature (London)
227:680-685.
13. Levine, M., R. Black, C. Ferreccio, R. Germanier, and the
Chilean Typhoid Committee. 1987. Large-scale field trials of
Ty2la live oral typhoid vaccine in enteric-coated capsule for-
mulation. Lancet ii:1049-1052.
14. Locht, C., P. A. Barstad, J. E. Coligan, L. Mayer, J. J. Munoz,
S. G. Smith, and J. M. Keith. 1986. Molecular cloning of
pertussis toxin genes. Nucleic Acids Res. 14:3251-3261.
15. McDermott, M., and J. Bienenstock. 1979. Evidence for a
common mucosal immunologic system. I. Migration of B immu-
noblasts into intestinal, respiratory and genital tissues. J. Im-
munol. 122:1892-1898.
16. Miller, E., L. A. E. Ashworth, A. Robinson, P. A. Waight, and
L. I. Irons. 1991. Phase II trial of whole-cell pertussis vaccine vs
an acellular vaccine containing agglutinogens. Lancet 337:70-
73.
17. Molina, C., and C. D. Parker. 1990. Murine antibody response
to oral infection with live aroA recombinant Salmonella dublin
vaccine strains expressing filamentous hemagglutinin antigen
from Bordetella pertussis. Infect. Immun. 58:2523-2528.
18. Murphy, J. R., L. Grez, L. Schlesinger, C. Ferreccio, S. Baqar,
C. Mufioz, S. S. Wasserman, G. Losonsky, J. G. Olson, and
M. M. Levine. 1991. Immunogenicity of Salmonella typhi Ty2la
vaccine for young children. Infect. Immun. 59:4291-4293.
19. Olander, R. M., A. Muotiala, M. Karvonen, T. Kuronen, and K.
Runeberg-Nyman. 1990. Serum antibody response to B. pertus-
sis TnS mutants, purified PT and FHA in two different mouse
strains and passive protection in the murine intranasal infection
model. Microb. Pathog. 8:37-45.
20. Parker, C. D., C. N. Molina, S. M. Kelly, R. Curtiss III, and J.
Yu. 1990. Live oral attenuated Salmonella typhimurium vaccine
VOL. 60, 1992
 o
n
 O
ctober 12, 2015 by University of Queensland Library
http://iai.asm
.org/
D
ow
nloaded from
 
4268 WALKER ET AL.
vectors which induce formation of antibody to Bordetella per-
tussis, p. 189-195. In C. R. Manclark (ed.), Proceedings of the
Sixth International Symposium on Pertussis. National Techni-
cal Information Service, Springfield, Va.
21. Pittman, M., B. L. Furman, and A. C. Wardlaw. 1980. Borde-
tella pertussis respiratory tract infection in the mouse: patho-
physiological responses. J. Infect. Dis. 142:56-66.
22. Robinson, A., L. I. Irons, and L. A. E. Ashworth. 1985. Pertussis
vaccine: present status and future prospects. Vaccine 3:11-22.
22a.Rohde, M. Unpublished observations.
23. Roth, J., M. Bendayan, E. Carlemaim, M. Villiger, and M.
Garavito. 1981. Enhancement of structural preservation and
immunocytochemical staining in low temperature embedded
pancreatic tissue. J. Histochem. Cytochem. 29:663-669.
24. Rudzik, R., R. L. Clancy, D. Y. E. Perey, R. P. Day, and J.
Bienenstock. 1975. Repopulation with IgA-containing cells of
bronchial and intestinal lamina propria after the transfer of
homologous Peyer's patch and bronchial lymphocytes. J. Im-
munol. 114:1599-1604.
25. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular
cloning: a laboratory manual, 2nd ed. Cold Spring Harbor
Laboratory Press, Cold Spring Harbor, N.Y.
26. Sanderson, K. E., and B. A. D. Stocker. 1987. Salmonella
typhimunium strains used in genetic analysis, p. 1220-1224. In
F. C. Neidhardt, J. L. Ingraham, K. B. Low, B. Magasanik, M.
Schaechter, and H. E. Umbarger (ed.), Eschenichia coli and
Salmonella typhimurium: cellular and molecular biology, vol. 2.
American Society for Microbiology, Washington, D.C.
27. Sansonetti, P. J., T. L. Hale, G. J. Damimin, C. Kapfer, H. H.
Collins, Jr., and S. B. Formal. 1983. Alterations in the pathoge-
nicity of Escherichia coli K-12 after transfer of plasmid and
chromosomal genes from Shigella flexneri. Infect. Immun.
39:1392-1402.
28. Sansonetti, P. J., D. J. Kopecko, and S. B. Formal. 1982.
Involvement of a plasmid in the invasive ability of Shigella
flexneri. Infect. Immun. 35:852-860.
29. Sato, Y., and H. Arai. 1972. Leukocytosis-promoting factor of
Bordetella pertussis. I. Purification and characterization. Infect.
Immun. 6:899-904.
30. Scharf, S. J. 1990. Cloning with PCR, p. 84-91. In M. A. Innis,
D. H. Gelfand, J. J. Sninsky, and T. J. White (ed.), PCR
protocols. Academic Press, London.
31. Schrauder, B., H. Blocker, R. Frank, and J. E. G. McCarthy.
1987. Inducible expression vectors incorporating the Esche-
richia coli atpE translational initiation region. Gene 52:279-283.
32. Slot, J. W., and H. J. Geuze. 1981. Sizing of protein A colloidal
gold probes for immunoelectron microscopy. J. Ultrastruct.
Res. 26:31-43.
33. Stainer, D. W., and M. J. Scholte. 1970. A simple chemically
defined medium for the production of phase I Bordetella pertus-
sis. J. Gen. Microbiol. 63:211-220.
34. Storsaeter, J., H. Hallander, C. P. Farrington, P. Olin, R.
Molby, and E. Miller. 1990. Secondary analysis of the efficacy of
two acellular pertussis vaccines evaluated in a Swedish phase
III trial. Vaccine 8:457-461.
35. Walker, M. J., M. Rohde, J. Wehland, and K. N. Timmis. 1991.
Construction of minitransposons for constitutive and inducible
expression of pertussis toxin in bvg-negative Bordetella bron-
chiseptica. Infect. Immun. 59:4238-4248.
36. Walker, M. J., J. Wehland, K. N. Timmis, B. Raupach, and
M. A. Schmidt. 1991. Characterization of murine monoclonal
antibodies that recognize defined epitopes of pertussis toxin and
neutralize its toxic effect on Chinese hamster ovary cells. Infect.
Immun. 59:4249-4251.
37. Yanisch-Perron, C., J. Vieira, and J. Messing. 1985. Improved
M13 phage cloning vectors and host strains: nucleotide se-
quences of the M13mpl8 and pUC19 vectors. Gene 33:103-119.
INFECT. IMMU'N.
 o
n
 O
ctober 12, 2015 by University of Queensland Library
http://iai.asm
.org/
D
ow
nloaded from
 
